March 28 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O:
VERTEX PHARMACEUTICALS INC - EXPECTS $400 MILLION IMPAIRMENT CHARGE FOR VX-264 - SEC FILING
Source text: [ID:n0000875320-25-000156]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.